FY2021 Earnings Forecast for DBV Technologies S.A. (DBVT) Issued By Jefferies Group
DBV Technologies S.A. (NASDAQ:DBVT) – Equities research analysts at Jefferies Group reduced their FY2021 earnings per share (EPS) estimates for DBV Technologies in a report issued on Monday. Jefferies Group analyst E. Yang now forecasts that the company will earn $4.32 per share for the year, down from their previous forecast of $4.55. Jefferies Group has a “Buy” rating and a $51.00 price objective on the stock.
A number of other brokerages have also recently issued reports on DBVT. BidaskClub cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Morgan Stanley restated an “overweight” rating and set a $72.00 price target (up from $70.00) on shares of DBV Technologies in a report on Friday, October 6th. Leerink Swann set a $49.00 price target on shares of DBV Technologies and gave the stock an “outperform” rating in a report on Monday. Zacks Investment Research cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a report on Thursday, August 31st. Finally, Deutsche Bank AG boosted their price target on shares of DBV Technologies from $46.00 to $56.00 in a report on Sunday, October 8th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $51.63.
WARNING: “FY2021 Earnings Forecast for DBV Technologies S.A. (DBVT) Issued By Jefferies Group” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/24/fy2021-earnings-forecast-for-dbv-technologies-s-a-dbvt-issued-by-jefferies-group.html.
Shares of DBV Technologies (NASDAQ DBVT) traded down 4.41% during midday trading on Tuesday, hitting $27.07. 2,758,680 shares of the stock were exchanged. The stock’s market capitalization is $1.25 billion. DBV Technologies has a 1-year low of $22.33 and a 1-year high of $50.57. The firm’s 50 day moving average is $44.48 and its 200-day moving average is $39.50.
A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its holdings in DBV Technologies by 3.1% during the first quarter. Goldman Sachs Group Inc. now owns 55,499 shares of the company’s stock worth $1,955,000 after purchasing an additional 1,647 shares during the last quarter. Alps Advisors Inc. boosted its holdings in DBV Technologies by 4.9% during the second quarter. Alps Advisors Inc. now owns 43,513 shares of the company’s stock worth $1,554,000 after purchasing an additional 2,040 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in DBV Technologies by 9.2% during the first quarter. Parametric Portfolio Associates LLC now owns 33,270 shares of the company’s stock worth $1,172,000 after purchasing an additional 2,794 shares during the last quarter. Exane Asset Management boosted its holdings in DBV Technologies by 3.9% during the second quarter. Exane Asset Management now owns 143,000 shares of the company’s stock worth $5,107,000 after purchasing an additional 5,394 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in DBV Technologies during the second quarter worth about $222,000. Institutional investors and hedge funds own 45.52% of the company’s stock.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.